VYNE Therapeutics Inc. 8-K

What Happened
On July 14, 2026, Yarrow Bioscience, Inc. published an investor presentation that VYNE Therapeutics Inc. made available on its Investor Relations website and filed as Exhibit 99.1 to a Form 8-K under Item 7.01 (Regulation FD Disclosure). The presentation can be viewed on VYNE’s site at https://vynetherapeutics.com/investors-media/events_presentations/.

Key Details

• Date filed: July 14, 2026 (Form 8-K).
• Disclosure type: Item 7.01 — Regulation FD Disclosure; Exhibit 99.1 is the investor presentation.
• The filing also includes Exhibit 104 (Cover Page Interactive Data File / Inline XBRL).
• The presentation was published by Yarrow Bioscience and posted by VYNE on its investors page.

Why It Matters
This filing informs investors that VYNE has publicly posted and formally filed an investor presentation from Yarrow Bioscience, ensuring broad access to the same material (Regulation FD compliance). Investors should review the linked presentation for any business updates or information that could affect their view of VYNE or its relationship with Yarrow. The 8-K itself does not contain additional financial results or executive changes.